timetalk uses cookies to ensure that we give you the best experience on our site. If you continue without changing your browser settings, we'll assume that you are agreeing to our use of cookies. Find out more by reading our cookies policy.
The British pharmaceutical company said that the deal will bring “uncertainty and risk†for its shareholders.
